

Press Release

May 10, 2017

MagForce AG reports highlights of Symposium for Focal Therapy in Glioblastoma at WFNOS 2017 Meeting

Lunch symposium saw record number of 300 attendees, high and increasing international interest for Company's NanoTherm® therapy

Berlin, Germany, and Nevada, USA, May 10, 2017 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, is pleased to announce that the Company was the host of the very successful Scientific Symposium titled "Focal Therapy in Glioblastoma - Current Status / What's New?" that was held at the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS) from May 4-7, 2017, in Zurich, Switzerland.

The one-hour lunch symposium featured three key note speeches:

Prof. Dr. Michael Weller, Chairman of the Department of Neurology at the University Hospital Zurich and President of EANO and WFNOS 2017, moderated the symposium and gave an introduction of the current state of the art for glioma treatment.

Secondly, Prof. Michael Vogelbaum, MD/PhD, Chair for Neuro-Oncology and Neurosurgery, Cleveland Clinic, presented a latest update on focal therapy in gliomas and reported some therapeutic successes with this approach.

As a third key note speaker, Prof. Walter Stummer, MD, Director of the Department of Neurosurgery at the University Hospital Münster, talked about new aspects of thermotherapy in brain tumors. He and his team are working with MagForce's NanoTherm® therapy in Münster and he presented an update and overview on their achievements and results.

Dr. Ben J. Lipps, CEO of MagForce AG and Magforce USA, Inc., commented: "The WFNOS meetings are amongst the most renowned international events in neuro-oncology and we are proud to have been part of WFNOS 2017 as a sponsor. We are very pleased to see such a high interest in our innovative NanoTherm® therapy from the scientific and medical community with 300 attendees at our symposium. The increased attention by a number of clinics and first-class neurosurgeons from other European countries is especially valuable to MagForce, since we continue to expand our commercialization to additional European sites in order to allow patient treatment with NanoTherm® therapy in their home countries.

Focal Therapy is an important option in the treatment of glioblastoma. These tumors are the most common and most aggressive type of tumor found in the brain. In Europe, around 13,000 glioblastoma cases are diagnosed each year. Prognosis for glioma patients is still dim as often times, even after the most successful surgery, residual microscopic tumor remains and usually regrows in direct vicinity of

Press Release

MagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • www.magforce.com

For further information:
Barbara von Frankenberg
VP Communications
& Investor Relations

bfrankenberg@magforce.com
T +49-30-308380-77
F +49-30-308380-99
M +49 173-2792768

the original resection cavity. For more local control of remaining tumour infiltration, the concept of thermotherapy for tumor ablation and as a radiosensitiser in glioma therapy could be very promising.

MagForce's NanoTherm[®] therapy is a new approach to the focal treatment of solid tumors. The method is based on the principle of introducing superparamagnetic nanoparticles (NanoTherm[®]) directly into a tumor. The particles are activated by an alternating magnetic field that changes its polarity up to 100,000 times per second, generating heat. With this new procedure, it is possible to combat the tumor from within, while sparing surrounding healthy tissue.

For more information on NanoTherm[®] therapy, please visit our [Download Center](#).

About WFNOS 2017 Meeting

Hosted by the European Association of Neuro-Oncology (EANO), the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS), held in Zurich from May 4-7, 2017, invited those involved in neuro-oncology to join this outstanding event for Neuro-Oncology worldwide. Owing to joint efforts of EANO, the US Society for Neuro-Oncology (SNO), the Asian Society for Neuro-Oncology (ASNO) and an increasing number of National Neuro-Oncology societies, WFNOS has become an active umbrella organization seeking to promote Neuro-Oncology in all aspects of care and research, and everywhere across the globe. Thus, WFNOS 2017 provided an opportunity to share up-to-date advances in basic science, translational and clinical research in a multidisciplinary setting. The four day programme featured among others, clinical and research updates, key note lectures and poster presentations as well as a symposium on the current status and future of focal therapy in glioblastoma.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm[®] therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm[®], NanoPlan[®], and NanoActivator[®] are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com.

Get to know our Technology: [video \(You Tube\)](#)

Stay informed and subscribe to our [mailing list](#).

Press Release

MagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • www.magforce.com

For further information:
Barbara von Frankenberg
VP Communications
& Investor Relations

bfrankenberg@magforce.com
T +49-30-308380-77
F +49-30-308380-99
M +49 173-2792768

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Press ReleaseMagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • www.magforce.com

For further information:
Barbara von Frankenberg
VP Communications
& Investor Relations

bfrankenberg@magforce.com
T +49-30-308380-77
F +49-30-308380-99
M +49 173-2792768